<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04779255</url>
  </required_header>
  <id_info>
    <org_study_id>2021-000304-38</org_study_id>
    <nct_id>NCT04779255</nct_id>
  </id_info>
  <brief_title>Pain Management During a Photodynamic Therapy Session on the Vertex for Actinic Keratosis: Tumescent Anesthesia Interest</brief_title>
  <acronym>ANTUKA</acronym>
  <official_title>Tumescent Anesthesia Interest in Pain Management During a Dynamic Phototherapy (PTD) Session in Vertex Actinic Keratosis Treatment: a Single-center Prospective Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study focus on the efficacity of tumescent anesthesia in pain management during a&#xD;
      photodynamic therapy on the vertex for treatment of actinic keratosis. To do this we carried&#xD;
      out a prospective, randomized, controlled, open-ended study. Our aim is to show a 40%&#xD;
      reduction in pain during photodynamic therapy session compared to a conventionally used&#xD;
      analgesic method (paracetamol + cold water)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Intensity Measure : evaluate the effectiveness of tumescent anesthesia compared to the control group in pain management during a dynamic vertex phototherapy session performed for the management of actinic keratoses.</measure>
    <time_frame>8 minutes</time_frame>
    <description>Score of the maximum numerical pain assessment scale from 0 to 10 (0=no pain; 10= pain as bas as can be) felt during the dynamic phototherapy session in both groups.&#xD;
This score will be collected at the end of the session.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Pain</condition>
  <condition>Actinic Keratosis</condition>
  <condition>Analgesia</condition>
  <condition>Phototerapy</condition>
  <condition>Vertex</condition>
  <arm_group>
    <arm_group_label>Tumescent anesthesia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient who will receive tumescent anesthesia as analgesic treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Painkillers and cold water</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient who will receive painkillers 1 hour before photodynamic therapy and cold water during session as analgesic treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Procedure (Tumesent anesthesia)</intervention_name>
    <description>Photodynamic therapy of vertex with a solution of 180 ml of tumescent anesthesia diffused over 1 hour in three different sub-deceasing points.</description>
    <arm_group_label>Tumescent anesthesia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control Arm (Paracetamol)</intervention_name>
    <description>Photodynamic therapy of vertex with 1g of paracetamol intake 1 hour before cold water is applied during the session.</description>
    <arm_group_label>Painkillers and cold water</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients over the age of 18&#xD;
&#xD;
          -  Diagnosis of clinical or histological actintic keratoses validated by a dermatologist&#xD;
&#xD;
          -  More than 4 vertex actinic keratoses lesions that can be treated with a dynamic&#xD;
             phototherapy session&#xD;
&#xD;
          -  Free subject, without guardianship or curatorship or subordination&#xD;
&#xD;
          -  Person affiliated or beneficiary of a social security plan&#xD;
&#xD;
          -  Informed and signed consent by the patient after clear and fair information about the&#xD;
             study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known lidocaine hydrochlostate hypersensitivity, local amide-binding anesthetics or&#xD;
             one of the excipients&#xD;
&#xD;
          -  Hypersensitivity to paracetamol or one of the excipients&#xD;
&#xD;
          -  Weight &lt; 50 kg&#xD;
&#xD;
          -  Patients with an elongated TQ interval at the ECG (&gt;450 ms in men and &gt;470 ms in&#xD;
             women)&#xD;
&#xD;
          -  Patients with recurrent porphyria&#xD;
&#xD;
          -  Severe hepato-cellular insufficient patients&#xD;
&#xD;
          -  Patients who have received treatment for actinic keratoses in the last three months&#xD;
             (cryotherapy, 5-fluorouracil, imiquinod, daylight-PTD)&#xD;
&#xD;
          -  Patients who have already participated in this study&#xD;
&#xD;
          -  People who do not have a social security plan or do not benefit from it through a&#xD;
             third party.&#xD;
&#xD;
          -  Persons with enhanced protection, namely minors, persons deprived of their liberty by&#xD;
             judicial or administrative decision, persons staying in a health or social&#xD;
             institution, adults under legal protection and finally the sick in an emergency&#xD;
             situation.&#xD;
&#xD;
          -  Pregnant or lactating women, women of childbearing age who do not have effective&#xD;
             contraception (hormonal/mechanical: per bone, injectable, transcutaneous, implantable,&#xD;
             intrauterine device, or surgical: tubal ligation, hysterectomy, total oophorectomy).&#xD;
&#xD;
          -  Concurrent participation in another clinical research study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Damien BOUTIN, Dr</last_name>
    <phone>05 49 44 44 59</phone>
    <phone_ext>+33</phone_ext>
    <email>damien.boutin@chu-poitiers.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BOUTIN Damien, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 26, 2021</study_first_submitted>
  <study_first_submitted_qc>March 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis, Actinic</mesh_term>
    <mesh_term>Keratosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

